Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials

Journal of the National Cancer Institute

Volumn 106, Issue 7, 2014, Pages

  Donovan, Kristine A ^a   Donovan, Heidi S ^b   Cella, David ^c   Gaines, Martha E ^d   Penson, Richard T ^e   Plaxe, Steven C ^f   Von Gruenigen, Vivian E ^g   Bruner, Deborah Watkins ^h   Reeve, Bryce B ⁱ   Wenzel, Lari ^j  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF WISCONSIN LAW SCHOOL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g AKRON CITY HOSPITAL   (United States)

^h EMORY UNIVERSITY   (United States)

ⁱ IL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); DENTAL HEALTH; DYSPHAGIA; HEAD AND NECK CANCER; HOARSENESS; HUMAN; HYPERSALIVATION; MOUTH PAIN; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PUBLICATION; QUALITY OF LIFE; QUALITY OF LIFE INDEX; SCORING SYSTEM; SELF REPORT; SHOULDER DISEASE; SKIN MANIFESTATION; SOCIAL STATUS; SYMPTOMATOLOGY; TASTE DISORDER; TRISMUS; XEROSTOMIA; ANOREXIA; CONSENSUS DEVELOPMENT; CONSTIPATION; DIARRHEA; FATIGUE; FEMALE; HEALTH STATUS; METHODOLOGY; NATIONAL HEALTH ORGANIZATION; NAUSEA; OVARY TUMOR; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; REVIEW; STANDARD; TREATMENT OUTCOME; UNITED STATES; VISCERAL PAIN; VOMITING;

ANTINEOPLASTIC AGENT;

OVARIAN NEOPLASMS; ANOREXIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CONSTIPATION; DIARRHEA; FATIGUE; FEMALE; HEALTH STATUS; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NAUSEA; QUALITY OF LIFE; QUESTIONNAIRES; SELF REPORT; TREATMENT OUTCOME; UNITED STATES; VISCERAL PAIN; VOMITING;

EID: 84905273624     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju128     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Bookman MA. Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int J Gynecol Cancer. 2005;15(Suppl 3):212-220.
3. Ozols RF. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J Clin Oncol. 2003;21(13):2451-2453.
4. Cleeland CS, Sloan JA, Group AO. Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards. J Pain Symptom Manage. 2010; 39 (6):1077-1085.
5. US Department of Health &Human Services Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009. http:// www.fda.gov/downloads/Drugs/Guidances/ UCM193282.pdf
6. Reeve BB, Mitchell SA, Dueck AC, et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst. 2014;106(7): dju129 doi:10.1093/jnci/dju129.
7. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapyovarian. J Clin Oncol. 2001;19(6):1809-1817.
8. Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOGNtx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13(6):741-748.
9. de Moor JS, de Moor CA, Basen-Engquist K, Kudelka A, Bevers MW, Cohen L. Optimism, distress, health-related quality of life, and change in cancer antigen 125 among patients with ovarian cancer undergoing chemotherapy. Psychosom Med. 2006;68(4):555-562.
10. Donovan HS, Hartenbach EM, Method MW. Patient-provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer. Gynecol Oncol. 2005;99(2):404-411.
11. Jensen SE, Rosenbloom SK, Beaumont JL, et al. A new index of priority symptoms in advanced ovarian cancer. Gynecol Oncol. 2011;120(2):214-219.
12. Kushner DM, Connor JP, Sanchez F, et al. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: A phase II trial. Gynecol Oncol. 2007;105(2):358-364.
13. Schmeler KM, Vadhan-Raj S, Ramirez PT, et al. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinumsensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009;113(2):210-215.
14. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Supp Care Cancer. 2005;13(4):219-227.
15. von Gruenigen VE, Huang HQ, Gil KM, et al. Assessment of factors that contribute to decreased quality of life in gynecologic oncology group ovarian cancer trials. Cancer. 2009;115(20):4857-4864.
16. von Gruenigen VE, Huang HQ, Gil KM, et al. A comparison of quality-of-life domains and clinical factors in ovarian cancer patients: A Gynecologic Oncology Group study. J Pain Symptom Manage. 2010;39(5):839-846.
17. Wenzel L, Huang HQ, Cella D, Walker JL, Armstrong DK. Validation of FACT/ GOG-AD subscale for ovarian cancerrelated abdominal discomfort: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008;110(1):60-64.
18. Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 2005;23(24):5605-5612.
19. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(4):437-443.
20. Wolf JK, Bodurka DC, Verschraegen C, et al. A phase II trial of oral capecitabine in patients with platinum-and taxane-refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol. 2006;102(3):468-474.
21. Bezjak A, Tu D, Bacon M, et al. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol. 2004;22(22):4595-4603.
22. Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol. 2001;19(5):1266-1274.
23. Hirte H, Vergote IB, Jeffrey JR, et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol. 2006;102(2):300-308.
24. Lakusta CM, Atkinson MJ, Robinson JW, Nation J, Taenzer PA, Campo MG. Quality of life in ovarian cancer patients receiving chemotherapy. Gynecol Oncol. 2001;81(3):490-495.
25. Greimel E, Bottomley A, Cull A, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer. 2003;39(10):1402-1408.
26. Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/ paclitaxel versus carboplatin/paclitaxel. J Clin Oncol. 2006;24(4):579-586.
27. Sehouli J, Stengel D, Oskay-Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2008;26(19):3176-3182.
28. Cull A, Howat S, Greimel E, et al. Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: A progress report. Eur J Cancer. 2001;37(1):47-53.
29. Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: A prospective longitudinal study. Gynecol Oncol. 2003;88(1):9-16.
30. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570-579.
31. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A qualityof-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376.
32. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A(9):1326-1336.
33. Donovan HS, Ward S, Sherwood P, Serlin RC. Evaluation of the Symptom Representation Questionnaire (SRQ) for assessing cancerrelated symptoms. J Pain Symptom Manage. 2008;35(3):242-257.
34. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291(22):2705-2712.
35. Han ES, Lin P, Wakabayashi M. Current status on biologic therapies in the treatment of epithelial ovarian cancer. Curr Treat Options Oncol. 2009;10(1-2):54-66